Selected research
Industry Research
Barbiturate Drugs Industry Research Report 2026
Market perspective
The global Barbiturate Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Barbiturate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Barbiturate Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Barbiturate Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Barbiturate Drugs include Teva Pharmaceutical, Sanofi, Merck, Mylan, Eli Lilly, Pfizer, Sumitomo Dainippon Pharma, Oak Pharmaceuticals and Meda pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Barbiturate Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Barbiturate Drugs Market by Company
Teva Pharmaceutical
Sanofi
Merck
Mylan
Eli Lilly
Pfizer
Sumitomo Dainippon Pharma
Oak Pharmaceuticals
Meda pharmaceuticals
Bausch Health
Barbiturate Drugs Segment by Type
Combination Drugs
Long-Acting Barbiturate
Short-Acting Barbiturate
Ultra-Short Acting Barbiturate
Barbiturate Drugs Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Barbiturate Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Barbiturate Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Barbiturate Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Barbiturate Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Barbiturate Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Barbiturate Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Barbiturate Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Combination Drugs
- Long-Acting Barbiturate
- Short-Acting Barbiturate
- Ultra-Short Acting Barbiturate
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Teva Pharmaceutical
- Sanofi
- Merck
- Mylan
- Eli Lilly
- Pfizer
- Sumitomo Dainippon Pharma
- Oak Pharmaceuticals
- Meda pharmaceuticals
- Bausch Health
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Barbiturate Drugs Market Size (2021-2032)
- 2.2.2 Global Barbiturate Drugs Sales (2021-2032)
- 2.2.3 Global Barbiturate Drugs Market Average Price (2021-2032)
- 2.3 Barbiturate Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Combination Drugs
- 2.3.3 Long-Acting Barbiturate
- 2.3.4 Short-Acting Barbiturate
- 2.3.5 Ultra-Short Acting Barbiturate
- 2.4 Barbiturate Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Barbiturate Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Barbiturate Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Barbiturate Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Barbiturate Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Barbiturate Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Barbiturate Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Barbiturate Drugs, Product Type & Application
- 3.8 Global Manufacturers of Barbiturate Drugs, Established Date
- 3.9 Global Barbiturate Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Barbiturate Drugs Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Barbiturate Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Barbiturate Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Barbiturate Drugs Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Eli Lilly
- 4.5.1 Eli Lilly Company Information
- 4.5.2 Eli Lilly Business Overview
- 4.5.3 Eli Lilly Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eli Lilly Barbiturate Drugs Product Portfolio
- 4.5.5 Eli Lilly Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Barbiturate Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Sumitomo Dainippon Pharma
- 4.7.1 Sumitomo Dainippon Pharma Company Information
- 4.7.2 Sumitomo Dainippon Pharma Business Overview
- 4.7.3 Sumitomo Dainippon Pharma Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sumitomo Dainippon Pharma Barbiturate Drugs Product Portfolio
- 4.7.5 Sumitomo Dainippon Pharma Recent Developments
- 4.8 Oak Pharmaceuticals
- 4.8.1 Oak Pharmaceuticals Company Information
- 4.8.2 Oak Pharmaceuticals Business Overview
- 4.8.3 Oak Pharmaceuticals Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Oak Pharmaceuticals Barbiturate Drugs Product Portfolio
- 4.8.5 Oak Pharmaceuticals Recent Developments
- 4.9 Meda pharmaceuticals
- 4.9.1 Meda pharmaceuticals Company Information
- 4.9.2 Meda pharmaceuticals Business Overview
- 4.9.3 Meda pharmaceuticals Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Meda pharmaceuticals Barbiturate Drugs Product Portfolio
- 4.9.5 Meda pharmaceuticals Recent Developments
- 4.10 Bausch Health
- 4.10.1 Bausch Health Company Information
- 4.10.2 Bausch Health Business Overview
- 4.10.3 Bausch Health Barbiturate Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bausch Health Barbiturate Drugs Product Portfolio
- 4.10.5 Bausch Health Recent Developments
5 Global Barbiturate Drugs Market Scenario by Region
- 5.1 Global Barbiturate Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Barbiturate Drugs Sales by Region: 2021-2032
- 5.2.1 Global Barbiturate Drugs Sales by Region: 2021-2026
- 5.2.2 Global Barbiturate Drugs Sales by Region: 2027-2032
- 5.3 Global Barbiturate Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Barbiturate Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Barbiturate Drugs Revenue by Region: 2027-2032
- 5.4 North America Barbiturate Drugs Market Facts & Figures by Country
- 5.4.1 North America Barbiturate Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Barbiturate Drugs Sales by Country (2021-2032)
- 5.4.3 North America Barbiturate Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Barbiturate Drugs Market Facts & Figures by Country
- 5.5.1 Europe Barbiturate Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Barbiturate Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Barbiturate Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Barbiturate Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Barbiturate Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Barbiturate Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Barbiturate Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Barbiturate Drugs Market Facts & Figures by Country
- 5.7.1 South America Barbiturate Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Barbiturate Drugs Sales by Country (2021-2032)
- 5.7.3 South America Barbiturate Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Barbiturate Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Barbiturate Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Barbiturate Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Barbiturate Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Barbiturate Drugs Sales by Type (2021-2032)
- 6.1.1 Global Barbiturate Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Barbiturate Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Barbiturate Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Barbiturate Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Barbiturate Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Barbiturate Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Barbiturate Drugs Sales by Application (2021-2032)
- 7.1.1 Global Barbiturate Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Barbiturate Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Barbiturate Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Barbiturate Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Barbiturate Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Barbiturate Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Barbiturate Drugs Value Chain Analysis
- 8.1.1 Barbiturate Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Barbiturate Drugs Production Mode & Process
- 8.2 Barbiturate Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Barbiturate Drugs Distributors
- 8.2.3 Barbiturate Drugs Customers
9 Global Barbiturate Drugs Analyzing Market Dynamics
- 9.1 Barbiturate Drugs Industry Trends
- 9.2 Barbiturate Drugs Industry Drivers
- 9.3 Barbiturate Drugs Industry Opportunities and Challenges
- 9.4 Barbiturate Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst